Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS–Kaposi’s sarcoma

References

• Northfelt DW, Dezube BJ, Thommes JA et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998;16:2445-51
   PubMed Web of Science ®Google Scholar
• Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. The Oncologist 2005;10:412-26
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Goedert JJ et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006;20:1645-54
   PubMed Web of Science ®Google Scholar
• Altekruse SF, Kosary CL, Krapcho M et al. SEER cancer statistics review, 1975–2007. 2010. Available at: http://seer.cancer.gov/csr/1975_2007/ [Last accessed November 2009]
   Google Scholar
• Bryan BA, Dyson OF, McCubrey JA, Akula SM. Biology of Kaposi’s sarcoma-associated herpes virus. Front Biosci 2005;10:2882-91
   PubMed Web of Science ®Google Scholar
• Liposomal KS drugs approved. GMHC Treat Issues 1996;4:8-9
   Google Scholar
• Paclitaxel for treating KS. Proj INF Perspect 1997;23(15)
   Google Scholar
• Bennett CL, Golub RM, Stinson TJ et al. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi’s sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:460-5
   PubMedGoogle Scholar
• Hjortsberg C, Persson U, Lidbrink E, et al. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi’s sarcoma. Acta Oncologica 1999;38:1063-7
   PubMed Web of Science ®Google Scholar
• Vanni T, Fonseca BAL, Polanczyk CA. Cost-effectiveness analysis comparing chemotherapy regimens in the treatment of AIDS-related Kaposi’s sarcoma in Brazil. HIV Clin Trials 2006;7:194-202
   PubMed Web of Science ®Google Scholar
• Egan T, Henry H. Cost-effectiveness of liposomal daunorubicin versus liposomal doxorubicin in Kaposi sarcoma. Value Health 1998;1:39
   Google Scholar
• Von Roenn J, Lee S, Cianfrocca M et al. Phase III study of paclitaxel (Pac) versus pegylated liposomal doxorubicin (PLD) for the treatment of advanced human immunodeficiency virus (HIV)-associated Kaposi’s sarcoma (KS): an eastern cooperative oncology group (ECOG) and AIDS malignancy consortium. J Clin Oncol–ASCO Annual Meeting Proceedings Part I 2007;25(20503)
   Google Scholar
• Cianfrocca M, Lee S, Von Roenn J et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010;116:3969-77
   PubMed Web of Science ®Google Scholar
• Analysource. Available at: https://www2.analysource.com/qry/as_menu.taf?_nc=5766067819826c07b3c0e0e324b03495 [Last accessed October 2012]
   Google Scholar
• Academic Medical Center. Confidential data. 2010
   Google Scholar
• Brixner DI, Oderda GM, Nickman NA, et al. Documentation of chemotherapy infusion preparation costs in academic- and community-based oncology practices. J Natl Compr Canc Netw 2006;4:197-208
   PubMedGoogle Scholar
• United States Department of Labor. CPI inflation medical care. Available at: http://www.bls.gov/cpi/ [Last accessed October 2012]
   Google Scholar
• Solimando DA. Paclitaxel package insert. Canc Investig 1997;15:503
   PubMed Web of Science ®Google Scholar
• Steward S, Jablonowski H, Goebel FD et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International pegylated liposomal doxorubicin study group. J Clin Oncol 1998;16:683-91
   PubMed Web of Science ®Google Scholar
• Centocor Ortho Biotech Products LP. Doxil package insert. Revised 09/2012
   Google Scholar
• Aujesky D, Smith KJ, Cornuz J, et al. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb and Haemostasis 2005;93:592-9
   PubMed Web of Science ®Google Scholar
• Stokes ME, Muehlenbein CE, Marciniak MD et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009;15:669-82
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Dale DC, Crawford J et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66
   PubMed Web of Science ®Google Scholar
• Goebel FD, Jablonowski H. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma -- official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal. Eur J Med Res. Dec 16 1999;4:507-13
   Google Scholar
• Tulpule A, Groopman J, Saville MW et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002;95:147-54
   PubMed Web of Science ®Google Scholar
• Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi’s sarcoma. AIDS 1999;13:283-4
   PubMed Web of Science ®Google Scholar
• Gill PS, Tulpule A, Espina BM et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 1999;17:1876-83
   PubMed Web of Science ®Google Scholar
• Welles L, Saville MW, Liteau J et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 1998;16:1112-21
   PubMed Web of Science ®Google Scholar
• Newcomer L. Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. Health Aff (Millwood) 2012;31:780-5
   PubMed Web of Science ®Google Scholar